Hydroxychloroquine

Generic Name
Hydroxychloroquine
Brand Names
Plaquenil, Sovuna
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3O
CAS Number
118-42-3
Unique Ingredient Identifier
4QWG6N8QKH
Background

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Hydroxychloroquine was granted FDA approval on 18 April 1955.

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.

Indication

Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions
Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
Associated Therapies
-
Clinical Trials
Related News

Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19

First Posted Date
2020-04-15
Last Posted Date
2021-08-12
Lead Sponsor
Centre Chirurgical Marie Lannelongue
Target Recruit Count
5
Registration Number
NCT04347980
Locations
🇫🇷

Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

Phase 1
Conditions
COVID-19
First Posted Date
2020-04-14
Last Posted Date
2020-07-01
Lead Sponsor
Perseverance Research Center, LLC
Target Recruit Count
80
Registration Number
NCT04344457
Locations
🇺🇸

Covidcraz 19, Llc, New Orleans, Louisiana, United States

🇺🇸

Perseverance Research Center, Scottsdale, Arizona, United States

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

Phase 3
Terminated
Conditions
COVID-19
Interventions
Drug: Hydroxychloroquine
Drug: Azithromycin
First Posted Date
2020-04-14
Last Posted Date
2022-01-21
Lead Sponsor
LCMC Health
Target Recruit Count
22
Registration Number
NCT04344444
Locations
🇺🇸

University Medical Center New Orleans, New Orleans, Louisiana, United States

Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus

First Posted Date
2020-04-14
Last Posted Date
2021-08-03
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
122
Registration Number
NCT04344379
Locations
🇫🇷

Hopial Avicenne, Bobigny, France

🇫🇷

Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France

🇫🇷

Hôpital Saint Antoine, Paris, France

and more 5 locations

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

Phase 3
Terminated
Conditions
COVID-19
Interventions
Drug: Hydroxychloroquine
First Posted Date
2020-04-14
Last Posted Date
2020-11-17
Lead Sponsor
Queen's Medical Center
Target Recruit Count
17
Registration Number
NCT04345692
Locations
🇺🇸

Queen's Medical Center, Honolulu, Hawaii, United States

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

First Posted Date
2020-04-13
Last Posted Date
2020-05-05
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
60
Registration Number
NCT04343768
Locations
🇮🇷

Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of

University of Utah COVID-19 Hydrochloroquine Trial

First Posted Date
2020-04-10
Last Posted Date
2023-02-15
Lead Sponsor
University of Utah
Target Recruit Count
368
Registration Number
NCT04342169
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

Hydroxychloroquine for COVID-19

First Posted Date
2020-04-10
Last Posted Date
2021-05-03
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
30
Registration Number
NCT04342221
Locations
🇩🇪

Institute for Tropical Medicine, Tübingen, Germany

🇩🇪

Robert-Bosch-Krankenhaus, Stuttgart, Germany

🇩🇪

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

and more 5 locations

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

First Posted Date
2020-04-10
Last Posted Date
2021-04-01
Lead Sponsor
Hugo Mendieta Zeron
Target Recruit Count
44
Registration Number
NCT04341493
Locations
🇲🇽

Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

First Posted Date
2020-04-10
Last Posted Date
2024-04-25
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
30
Registration Number
NCT04341727
Locations
🇺🇸

Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy